Out of that list, my bet would be on number 6 (Hem/Onc) or 7 (Cardio) and if I were them, I would acquire someone with strong international presence (which GILD lacks), maybe an EU-based company. And I would make it large enough to matter. But obviously this would be a big change in their M&A philosophy.